Drug Profile
Research programme: amyotrophic lateral sclerosis gene therapy - ALS Therapy Development Institute/Asklepios Biopharmaceutical
Latest Information Update: 27 May 2021
Price :
$50
*
At a glance
- Originator ALS Therapy Development Institute; Asklepios BioPharmaceutical
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 01 Jan 2013 No development reported for Amyotrophic lateral sclerosis in USA (Parenteral)
- 20 Jan 2009 Early research in Amyotrophic lateral sclerosis in USA (Parenteral)